The investigational drug Abiraterone, designed for the treatment of men with advanced prostate cancer who have failed chemotherapy has not yet been approved by the FDA. Because of the extraordinarily positive results that were obtained on the phase III trials (which were stopped early because of these fantastic results) the pharmaceutical manufacturer of the drug has worked with the FDA to allow an expanded access, compassionate usage program while formal approval of the FDA is pending.

The following web page describes the program:

General Information

This website is designed for health care professionals to learn more about an expanded access program (EAP) to provide subjects with the opportunity for treatment with an investigational drug, abiraterone acetate, before Marketing Authorization. Abiraterone acetate is an investigational drug and is not curren